Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study Vierling, J. M., Sobhonslidsuk, A., Papatheodoridis, G., Assy, N., Rosenberg, W., Guyader, D., Dev, A., Gordon, S. C., Pol, S., Luketic, V. A., Khemichian, S., Evans, B., Morgan, L., Li, M., Talwani, R., Arduino, J. M., Kwo, P. ELSEVIER SCIENCE BV. 2017: S521–S522
View details for DOI 10.1016/S0168-8278(17)31445-9
View details for Web of Science ID 000401056601288